Vivek Ramaswamy

Vivek Ramaswamy (born August 9, 1985) is an American entrepreneur in the biotechnology sector. He is the founder and executive chairman of the biopharmaceutical company Roivant Sciences. Prior to founding Roivant in 2014, Ramaswamy co-founded a technology company and was a partner at an investment firm. He is a graduate of Harvard College and Yale Law School and has written about the undue influence of corporate power on American democracy.

Vivek Ramaswamy
Born (1985-08-09) August 9, 1985
Cincinnati, Ohio, U.S.
Education
Net worth$600 million (April 2017)
Title

As of April 2017, he is worth an estimated $600 million.[1]

Personal life and education

He is the eldest son in his family. His father worked at General Electric and his mother, Geetha Ramaswamy, is a geriatric psychiatrist.[2]

Ramaswamy graduated from St. Xavier High School in Cincinnati in 2003.[3] He graduated summa cum laude from Harvard College with an A.B. in biology. He then received a J.D. from Yale Law School, where his studies were supported by The Paul & Daisy Soros Fellowships for New Americans. [4]

Ramaswamy is married to Apoorva Tewari Ramaswamy, an otolaryngologist. In 2020, after four weeks of maternity leave, she returned to work as a frontline healthcare worker during the COVID-19 pandemic and was infected while treating patients.[5] Apoorva has recovered from the coronavirus.[6]

Career

In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009 by the Ewing Marion Kauffman Foundation. Ramaswamy worked at QVT Financial from 2007 to 2014, where he was a partner and co-managed the firm’s biotech portfolio.[7] Ramaswamy appeared on the cover of Forbes magazine in 2015.[8]

Ramaswamy is the founder of the pharmaceutical company Roivant Sciences. Ramaswamy served as CEO of the company until 2021 when he became executive chairman. Roivant is focused on applying technology to drug development and has built numerous subsidiary biotech and healthcare technology companies, several of which are publicly listed. The initial public offering for Roivant subsidiary Axovant in 2015 raised $360 million.[9]

Ramaswamy served on the Board of Directors of Myovant Sciences, a subsidiary of Roivant Sciences focused on the treatment of women’s health diseases and other endocrine-related disorders. Myovant, formed in April 2016, raised $218 million in its initial public offering, the largest biotech IPO of 2016.[10]

Ramaswamy serves on the Board of Directors of Sumitovant Biopharma. Sumitovant is the result of a $3 billion transaction in 2019 which transferred ownership stakes in five companies in the Roivant family, and includes investigational medicines which generated four successful Phase 3 studies in 2019.[11]

In 2020, Ramaswamy served on the Ohio COVID-19 Response Team.[12]

In January 2021, Ramaswamy stepped down as CEO of Roivant Sciences and became executive chairman of the company's board.[13]

Publications
  • The Chimera Question, New York Times, July 16, 2007[14]
  • This Pharma Company Stays Innovative by Doing Two Things, Harvard Business Review, March 14, 2017[15]
  • The ‘Stakeholders’ vs. the People, Wall Street Journal, February 12, 2020[16]
  • COVID-19 and American Identity, The Dispatch, July 14, 2020[17]
  • Antitrust Can't Bust a Monopoly of Ideas, Wall Street Journal, August 5, 2020[18]
  • End Corporate Privilege by Limiting Limited Liability, Newsweek, October 9, 2020[19]
  • The Pluralism Within, National Review, October 29, 2020[20]
  • Save the Constitution from Big Tech, Wall Street Journal, January 11, 2021[21]
  • ‘Stakeholder Capitalism’ Review: The Global, Olympian ‘We’, Wall Street Journal, January 25, 2021[22]

References
  1. Kroll, Luisa (April 4, 2017). "America's Richest Entrepreneurs Under 40 2016". Forbes. Retrieved April 5, 2017.
  2. "America's Richest Entrepreneurs Under 40: Vivek Ramaswamy".
  3. Schulte, Becky (July 25, 2015). "July 2015". St. Xavier High School E-news (Mailing list). St. Xavier High School. Retrieved July 26, 2015.
  4. "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air".
  5. "Swedish ambassador to the US on her country's path to 'herd immunity' against the coronavirus". Fox News. 2020-05-07. Retrieved 2020-05-21.
  6. "COVID-19 How It Ends". I am Bio. Retrieved 2020-07-10.
  7. "The 29 Year Old Behind The Giant Biotech IPO That Rose By 90% Speaks".
  8. "Forbes September 28, 2015 Vivek Ramaswamy Boy in the Bubble (Magazine: Finance, Business)". IndigoMistBooks. Retrieved 2020-05-13.
  9. Spalding, Rebecca. "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg.
  10. "Biggest Biotech IPO Of 2016 Is Launched By 31 Year Old".
  11. "Sumitomo Dainippon and Roivant Close Deal to Form Sumitovant Biopharma". BioSpace. Retrieved 2020-06-26.
  12. "Swedish ambassador to the US on her country's path to 'herd immunity' against the coronavirus". Fox News. 2020-05-07. Retrieved 2020-05-13.
  13. "Roivant's Ramaswamy Steps Down as CEO, Becomes Executive Chairman". BioSpace. Retrieved 2021-01-28.
  14. "The chimera question". Boston.com. Retrieved 2020-02-27.
  15. "This Pharma Company Stays Innovative by Doing Two Things". Harvard Business Review. 2017-03-14. ISSN 0017-8012. Retrieved 2020-02-27.
  16. "The 'Stakeholders' vs. the People". Wall Street Journal. 2020-02-13. ISSN 0099-9660. Retrieved 2020-02-27.
  17. "COVID-19 and American Identity". thedispatch.com. Retrieved 2020-08-04.
  18. "Opinion | Antitrust Can't Bust a Monopoly of Ideas". Wall Street Journal. 2020-08-05. ISSN 0099-9660. Retrieved 2020-08-14.
  19. "End corporate privilege by limiting limited liability | Opinion". Newsweek. 2020-10-09. Retrieved 2020-10-14.
  20. "The Pluralism Within". National Review. 2020-10-29. Retrieved 2020-11-10.
  21. "Save the Constitution From Big Tech". Wall Street Journal. 2021-01-11. Retrieved 2021-01-21.
  22. "'Stakeholder Capitalism' Review: The Global, Olympian 'We'". Wall Street Journal. 2021-01-25. Retrieved 2021-01-29.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.